RegenXBio (RGNX) Stock Forecast & Price Target

Compare

1,041 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RGNX Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

RegenXBio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RGNX Stock 12 Month Forecast

Average Price Target

$36.25

▲(224.82% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for RegenXBio in the last 3 months. The average price target is $36.25 with a high forecast of $52.00 and a low forecast of $19.00. The average price target represents a 224.82% change from the last price of $11.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","17":"$17","29":"$29","41":"$41","53":"$53"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,17,29,41,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,17.29230769230769,20.184615384615384,23.076923076923077,25.96923076923077,28.861538461538462,31.753846153846155,34.646153846153844,37.53846153846154,40.43076923076923,43.323076923076925,46.215384615384615,49.107692307692304,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,16.08076923076923,17.76153846153846,19.442307692307693,21.123076923076923,22.803846153846152,24.484615384615385,26.165384615384617,27.846153846153847,29.526923076923076,31.207692307692305,32.88846153846154,34.56923076923077,{"y":36.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.4,14.753846153846155,15.107692307692307,15.461538461538462,15.815384615384616,16.16923076923077,16.52307692307692,16.876923076923077,17.23076923076923,17.584615384615386,17.93846153846154,18.29230769230769,18.646153846153844,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.77,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$52.00

Average Price Target$36.25

Lowest Price Target$19.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yi Chen

H.C. Wainwright

$34

Buy

204.66%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Armata Pharmaceuticals (NYSE MKT: ARMP) and Halozyme (NASDAQ: HALO)

Annabel Samimy

Stifel Nicolaus

$45

Buy

303.23%

Upside

Reiterated

01/28/26

RegenXBio: Clinical Hold on RGX-111/121 Seen as Manageable Timing Issue, Core Gene Therapy Platform and Key Value Drivers Remain Intact Supporting Buy Rating

William Maughan

Clear Street

$50

Buy

348.03%

Upside

Reiterated

01/28/26

Regenxbio clinical hold does not change thesis, says Clear StreetRegenxbio clinical hold does not change thesis, says Clear Street

Daniil Gataulin

Chardan Capital

$52

Buy

365.95%

Upside

Reiterated

01/28/26

Chardan Capital Remains a Buy on RegenXBio (RGNX)

Mani Foroohar

Leerink Partners

Buy

―

Reiterated

01/28/26

Regenxbio selloff 'an overreaction' to clinical hold, says LeerinkRegenxbio selloff 'an overreaction' to clinical hold, says Leerink

Eliana Merle

Barclays

$37

Buy

231.54%

Upside

Reiterated

01/27/26

Regenxbio assumed with an Overweight at BarclaysRegenxbio assumed with an Overweight at Barclays

Alec Stranahan

Bank of America Securities

$28

Buy

150.90%

Upside

Reiterated

01/15/26

Bank of America Securities Sticks to Their Buy Rating for RegenXBio (RGNX)

Judah Frommer

Morgan Stanley

$25

Buy

124.01%

Upside

Reiterated

01/12/26

RegenXBio: Advancing Gene Therapy Pipeline and Near‑Term Regulatory Catalysts Underpin Buy Rating

Luca Issi

RBC Capital

$17→$19

Buy

70.25%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Mind Medicine (NASDAQ: MNMD) and Tandem Diabetes Care (NASDAQ: TNDM)

Sean McCutcheon

Raymond James

$29

Buy

159.86%

Upside

Reiterated

09/05/25

RegenXBio (RGNX) Receives a Buy from Raymond James

Paul Choi

Goldman Sachs

$14

Hold

25.45%

Upside

Reiterated

09/05/25

Goldman Sachs Sticks to Its Hold Rating for RegenXBio (RGNX)

Brian Skorney

Robert W. Baird

$39

Buy

249.46%

Upside

Reiterated

03/19/25

Bairds Brian Skorney Comments on Regenxbio Inc. (RGNX): We also think its favorable that REGENXBIO is able to learn from Elevidys faultsBaird analyst Brian Skorney reiterated an Outperform rating and $39.00 price target on Regenxbio Inc. (NASDAQ: RGNX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yi Chen

H.C. Wainwright

$34

Buy

204.66%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Armata Pharmaceuticals (NYSE MKT: ARMP) and Halozyme (NASDAQ: HALO)

Annabel Samimy

Stifel Nicolaus

$45

Buy

303.23%

Upside

Reiterated

01/28/26

RegenXBio: Clinical Hold on RGX-111/121 Seen as Manageable Timing Issue, Core Gene Therapy Platform and Key Value Drivers Remain Intact Supporting Buy Rating

William Maughan

Clear Street

$50

Buy

348.03%

Upside

Reiterated

01/28/26

Regenxbio clinical hold does not change thesis, says Clear StreetRegenxbio clinical hold does not change thesis, says Clear Street

Daniil Gataulin

Chardan Capital

$52

Buy

365.95%

Upside

Reiterated

01/28/26

Chardan Capital Remains a Buy on RegenXBio (RGNX)

Mani Foroohar

Leerink Partners

Buy

―

Reiterated

01/28/26

Regenxbio selloff 'an overreaction' to clinical hold, says LeerinkRegenxbio selloff 'an overreaction' to clinical hold, says Leerink

Eliana Merle

Barclays

$37

Buy

231.54%

Upside

Reiterated

01/27/26

Regenxbio assumed with an Overweight at BarclaysRegenxbio assumed with an Overweight at Barclays

Alec Stranahan

Bank of America Securities

$28

Buy

150.90%

Upside

Reiterated

01/15/26

Bank of America Securities Sticks to Their Buy Rating for RegenXBio (RGNX)

Judah Frommer

Morgan Stanley

$25

Buy

124.01%

Upside

Reiterated

01/12/26

RegenXBio: Advancing Gene Therapy Pipeline and Near‑Term Regulatory Catalysts Underpin Buy Rating

Luca Issi

RBC Capital

$17→$19

Buy

70.25%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Mind Medicine (NASDAQ: MNMD) and Tandem Diabetes Care (NASDAQ: TNDM)

Sean McCutcheon

Raymond James

$29

Buy

159.86%

Upside

Reiterated

09/05/25

RegenXBio (RGNX) Receives a Buy from Raymond James

Paul Choi

Goldman Sachs

$14

Hold

25.45%

Upside

Reiterated

09/05/25

Goldman Sachs Sticks to Its Hold Rating for RegenXBio (RGNX)

Brian Skorney

Robert W. Baird

$39

Buy

249.46%

Upside

Reiterated

03/19/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering RegenXBio

3 Months

xxx

Success Rate

8/11 ratings generated profit

Average Return

+17.91%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +17.91% per trade.

1 Year

Judah FrommerMorgan Stanley

Success Rate

10/11 ratings generated profit

Average Return

+71.19%

reiterated a buy rating 20 days ago

Copying Judah Frommer's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +71.19% per trade.

2 Years

xxx

Success Rate

10/11 ratings generated profit

Average Return

+74.62%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +74.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGNX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RGNX has received 23 Buy Ratings, 28 Hold Ratings, and 0 Sell Ratings. RGNX average Analyst price target in the past 3 months is 36.25.

Each month's total comprises the sum of three months' worth of ratings.

RGNX Financial Forecast

RGNX Earnings Forecast

Next quarter’s earnings estimate for RGNX is -$0.77 with a range of -$1.65 to $0.78. The previous quarter’s EPS was -$1.20. RGNX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year RGNX has Performed in-line its overall industry.

RGNX Sales Forecast

Next quarter’s sales forecast for RGNX is $56.36M with a range of $20.00M to $140.00M. The previous quarter’s sales results were $29.73M. RGNX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year RGNX has Performed in-line its overall industry.

RGNX Stock Forecast FAQ

What is RGNX’s average 12-month price target, according to analysts?

Based on analyst ratings, RegenXBio’s 12-month average price target is 36.25.

What is RGNX’s upside potential, based on the analysts’ average price target?

RegenXBio has 224.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RGNX a Buy, Sell or Hold?

RegenXBio has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is RegenXBio’s price target?

The average price target for RegenXBio is 36.25. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $19.00. The average price target represents 224.82% Increase from the current price of $11.16.

What do analysts say about RegenXBio?

RegenXBio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of RGNX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

RegenXBio (RGNX) Stock Forecast & Price Target

RGNX Analyst Ratings

RGNX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering RegenXBio

RGNX Analyst Recommendation Trends

RGNX Financial Forecast

RGNX Earnings Forecast

RGNX Sales Forecast

RGNX Stock Forecast FAQ

Detailed List of Analyst Forecasts